Last updated on April 2018

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies


Brief description of study

This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase. Once RP2D is determined from either the intradermal or subcutaneous group, an additional 40 patients evaluable for response may be enrolled as an expansion cohort at this dose and route of administration to confirm safety and tolerability. Separate from the dose-ascending cohort and RP2D expansion cohort described previously, and once the intradermal dose-ascending cohort is completed, up to 20 MDS patients who are refractory to treatment with hypomethylating agents (HMAs) will be enrolled into an MDS expansion cohort. Of these 20 MDS patients, one-half will receive DSP-7888 at 10.5 mg according to the modified schedule employed in Phase 1 (every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks; [MDS Cohort 1]). The other half of the MDS patients will receive DSP-7888 at 10.5 mg in an alternative dosing schedule where DSP-7888 is administered every 2 weeks until Week 24, after which it will be administered every 4 weeks (MDS Cohort 2).

Clinical Study Identifier: NCT02498665

Contact Investigators or Research Sites near you

Start Over

Emma Judson, PhD

Emory University Winship Cancer Institute
Atlanta, GA United States
  Connect »

Crystal Kohn (Speaks), MPH

USOR - TX Oncology Austin
Austin, TX United States
  Connect »

Crystal Kohn (Speaks), MPH

USOR -TX Oncology Dallas
Dallas, TX United States
  Connect »

Crystal Kohn (Speaks), MPH

USOR - TX Oncology Tyler
Tyler, TX United States
  Connect »

Crystal Kohn (Speaks), MPH

USOR - VA Cancer Specialists
Fairfax, VA United States
  Connect »

Crystal Kohn (Speaks), MPH

USOR - VA Oncology Associates
Norfolk, VA United States
  Connect »

Crystal Kohn (Speaks), MPH

USOR - Rocky Mountain Cancer Center
Denver, CO United States
  Connect »

Boston Biomedical

Horizon Oncology Research
Lafayette, IN United States
  Connect »

Boston Biomedical

Gabrail Cancer Center Research
Canton, OH United States
  Connect »